NCIC CLINICAL TRIALS GROUP

GYNECOLOGY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: CHURCHILL B

APRIL 28, 2012 – 9:00 A.M. - 3:30 P.M.

CHAIRS: MICHAEL FUNG KEE FUNG AND HAL HIRTE

(3:30 P.M. – 4:30 P.M. EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To review the results of recent clinical trials in gynecologic oncology and to enhance understandings of the trials’ results with respect to intervention adoption.
- To review aspects of standard care of patients with gynecologic cancer specifically as these practices relate to new NCIC CTG priority initiatives (e.g., ovarian cancer [first line therapy; therapy for platin-resistant disease], cervical cancer).
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to gynecologic cancers.
- To review QoL outcomes and the implications of adopting trial results and to discuss QoL methodological issues as these relate to gynecologic cancers.

9:00 a.m.  GYNE COMMITTEE – WELCOME  M. FUNG-KEE-FUNG/H. HIRTE/R. MEYER
- INTRODUCTION OF M. FUNG-KEE-FUNG AND H. HIRTE AS INCOMING CO-CHAIRS
- ACKNOWLEDGEMENT OF GAVIN STUART AND AMIT OZA AS OUTGOING CO-CHAIRS
- BRIEF OVERVIEW OF NEW MEETING STRUCTURE

9:15 a.m.  BRAINSTORMING SESSION
- SETTING THE STAGE
- REVIEW OF SURVEY AND INTERVIEWS
- FEEDBACK AND DISCUSSION
- KEY DISCUSSION POINTS (GENERATED FROM SURVEY)
- HOW CAN WE GET THE MOST OUT OF THE SPRING MEETING?
- HOW CAN WE HAVE GREATER INTEGRATION AND COLLABORATION IN THE WIDER GYN ONCOLOGY COMMUNITY?

10:30 a.m.  BREAK
10:45 a.m. **NCIC CTG TRIALS UPDATE:**

OV.21  
CX.5  

H. MacKay/D. Provencher  
M. Plante

12:00 p.m  **LUNCH**

1:30 p.m. **TRIALS UPDATE**

**ENDOMETRIUM**

→ Phase III  
- EN5 (QoL & SAQ analysis)  
- EN7/PORTEC 3  
  
H. Hirte  
P. Bessette/A. Fyles

→ IND STUDIES  
  
- IND.192 (deforolimus)  
  
A. Oza

**CERVIX**

→ Phase III  
  
- CXC1/GOG 0219  
  
H. Hirte

→ IND STUDIES  
  
- IND199 (tepsirolimus)  
  
A. Tinker

**OVARY**

→ OV.19/ICON7  
  
A. Oza

→ OV.18/ICON6  
  
H. Hirte

→ OV.17/CALYPSO  
  
M. Heywood/M. Brundage

→ SYMPTOM BENEFIT PILOT UPDATE (ANZGOG)  
  
A. Oza

2:30 p.m. **GYNE CSTB WORKING GROUP REPORT**  
  
A. Mes-Masson

2:45 p.m. **IND ACTIVITY/BASIC SCIENCE UPDATE**  
  
H. Hirte

3:00 p.m. **GYNE COMMITTEE LIASONS/REPS REPORT**

→ CLINICAL RESEARCH ASSOCIATES  
  
L. Tinker

→ ECONOMICS  
  
J.S. Kwon

→ LAY  
  
M. Manojlovich

→ PHARMACY  
  
Wendy Won

→ QUALITY OF LIFE  
  
?

3:15 p.m. **NCI US GCSG AND GCIG UPDATES**  
  
M. Fung-Kee-Fung/H. Hirte

3:25 p.m. **OTHER BUSINESS**

3:30 p.m. **ADJOURN**

3:30 – 4:30 **GYNE EXECUTIVE (CLOSED)**

*Room: Baker*